SinoPharm-B (02627.HK): Phase I clinical trials of quadrivalent influenza virus subunit vaccine (adjuvant) and trivalent influenza virus subunit vaccine (adjuvant) have been initiated.

Zhitan Finance and Economics App news, China Hui Biological-B (02627.HK) announced that the group has recently initiated Phase I clinical trials for the quadrivalent influenza virus subunit vaccine (adjuvant) and trivalent influenza virus subunit vaccine (adjuvant). The group has obtained approval for new drug clinical trial applications from the National Medical Products Administration of the People's Republic of China for the quadrivalent influenza virus subunit vaccine (adjuvant) in July 2024 and for the trivalent influenza virus subunit vaccine (adjuvant) in October 2024.